<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04999566</url>
  </required_header>
  <id_info>
    <org_study_id>2020-02531</org_study_id>
    <nct_id>NCT04999566</nct_id>
  </id_info>
  <brief_title>Cardiac Manifestation and Inherited Metabolic Diseases</brief_title>
  <official_title>Cardiac Manifestations in Adult Patients With Inherited Metabolic Disease: a Case Series</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Lausanne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Lausanne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to report and describe cardiac manifestations associated with IMD in&#xD;
      a cohort of patients followed in a reference center for rare diseases (Lausanne University&#xD;
      Hospital, CHUV) from 2017-2020.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inherited metabolic diseases (IMD) are genetic disorders resulting from an enzyme defect&#xD;
      and/or transport proteins in metabolic pathways affecting proteins, fat, carbohydrate&#xD;
      metabolism or impaired organelle function. As IMDs can affect the primary sources of energy&#xD;
      (glycogen, fatty acids), they can lead to cardiac dysfunction. Although most of IMDs are&#xD;
      multisystemic diseases, in some cases, the cardiac dysfunction they cause is the main&#xD;
      clinical feature and source of major complications which will determine the prognosis, like&#xD;
      heart failure, ventricular arrythmias or even sudden death. Information regarding cardiac&#xD;
      manifestations in adult IMDs is currently scarce and little is known about their clinical and&#xD;
      radiological characteristics.&#xD;
&#xD;
      A database was created in 2017 including all patients with IMD followed at the Adult&#xD;
      Metabolic Clinic in the CHUV. This database was part of a protocol submitted and approved by&#xD;
      the Ethics committee (# 2017-02328). The results of this first analysis were published in the&#xD;
      Journal of Orphan Rare Diseases. Investigators will use this database to identify all the&#xD;
      patients who had cardiac examination. Only patients from the Lausanne University Hospital&#xD;
      followed jointly with the Division of Cardiology will be included in the analysis. Electronic&#xD;
      and paper patient charts from the Division of Genetic Medicine and Division of Cardiology&#xD;
      (Lausanne University Hospital) will be reviewed for type of IMD and cardiac investigations&#xD;
      (cardiac ultrasound, multiple resonance Imaging, electrocardiogram). All variables will be&#xD;
      entered in an excel database.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">August 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Specific diagnosis of Inborn Errors of Metabolism listed by their frequency</measure>
    <time_frame>Day 1</time_frame>
    <description>Clinical outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Age at diagnosis (years/months)</measure>
    <time_frame>Day 1</time_frame>
    <description>Clinical outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Current age (years/months)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Clinical outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight (kg)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Clinical outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Height (cm)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Clinical outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BMI (kg/m^2)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Clinical outcome. Weight and height will be combined to report BMI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac involvement</measure>
    <time_frame>3 years</time_frame>
    <description>Type of complications (restrictive cardiomyopathy, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrythmia, heart failure, valvlulopathy, cardiomegaly, thrombosis)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular mass (g/m^2)</measure>
    <time_frame>3 years</time_frame>
    <description>Cardiac ultrasound and multiple resonance imaging description of left ventricular mass</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular volume (cc/m^2)</measure>
    <time_frame>3 years</time_frame>
    <description>Cardiac ultrasound and multiple resonance imaging description of left ventricular volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Right ventricular volume (cc/m^2)</measure>
    <time_frame>3 years</time_frame>
    <description>Cardiac ultrasound and multiple resonance imaging description of right ventricular volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular diameter (mm)</measure>
    <time_frame>3 years</time_frame>
    <description>Cardiac ultrasound and multiple resonance imaging description of left ventricular diameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular ejection fraction (%)</measure>
    <time_frame>3 years</time_frame>
    <description>Cardiac ultrasound and multiple resonance imaging description of left ventricular ejection fraction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Right ventricular ejection fraction (%)</measure>
    <time_frame>3 years</time_frame>
    <description>Cardiac ultrasound and multiple resonance imaging description of right ventricular ejection fraction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>aortic root diameter (mm)</measure>
    <time_frame>3 years</time_frame>
    <description>Cardiac ultrasound and multiple resonance imaging description of aortic root diameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Additional cardiac investigations</measure>
    <time_frame>3 years</time_frame>
    <description>ECG-QT interval</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specific treatment for inherited metabolic diseases</measure>
    <time_frame>3 years</time_frame>
    <description>Treatment specific to each diseases including ammonia scavenger, enzyme replacement therapy, vitamin cofactors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gender (Male/Female)</measure>
    <time_frame>Day 1</time_frame>
    <description>Demography outcome</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Metabolism, Inborn Errors</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatient clinic for Adult patients with inherited metabolic diseases (IMD) from the&#xD;
        Lausanne University Hospital (Division of Genetic Medicine)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All IMD adult patients followed at the adult metabolic clinic at the Lausanne&#xD;
             University Hospital from 2017 to 2020 with cardiac investigations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 16 years. Any document attesting a refusal to participate will exclude the data&#xD;
             entry of the concerned patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christel Tran, MD</last_name>
    <phone>+41213143680</phone>
    <email>christel.tran@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tobias Rutz, MD</last_name>
    <phone>+4121 314 48 00</phone>
    <email>tobias.rutz@chuv.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lausanne University Hospital</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christel Tran, MD</last_name>
      <phone>+41213143680</phone>
      <email>christel.tran@chuv.ch</email>
    </contact>
    <contact_backup>
      <last_name>Tobias Rutz, MD</last_name>
      <phone>+41213144800</phone>
      <email>tobias.rutz@chuv.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/32811506/</url>
    <description>Article open-access</description>
  </link>
  <results_reference>
    <citation>Gariani K, Nascimento M, Superti-Furga A, Tran C. Clouds over IMD? Perspectives for inherited metabolic diseases in adults from a retrospective cohort study in two Swiss adult metabolic clinics. Orphanet J Rare Dis. 2020 Aug 18;15(1):210. doi: 10.1186/s13023-020-01471-z.</citation>
    <PMID>32811506</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>August 7, 2021</last_update_submitted>
  <last_update_submitted_qc>August 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Lausanne</investigator_affiliation>
    <investigator_full_name>Christel Tran</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cardiac involvement</keyword>
  <keyword>Inborn errors of metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

